Postoperative pathology is clearly diagnosed as invasive breast cancer.
Estrogen receptor (ER) or progesterone receptor (PR) positive, HER2 negative.
Available with Formalin-Fixed and Parrffin-Embedded (FFPE) tumor tissue.
Stage I-II patients who have received surgery (breast-conserving or mastectomy) and the pathological staging is pT1-2N0-1M0 or pT3N0M0.
The patient had not received systemic systemic treatment (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy) before enrollment.
Signed an informed consent form.
You may not be if
Breast cancer patients whose clinical or pathological stage is T4, N2-3 or M1.
Known human immunodeficiency virus infection (HIV) or acquired immunodeficiency syndrome (AIDS) related diseases.
Other psychiatric disorders that may interfere with the judgment of the study results, or abnormal laboratory tests; and who, in the judgment of the investigator, are considered unfit to participate in the study.
Subjects with allogeneic organ transplants requiring immunosuppressive therapy.
Hormone receptors ER and PR are negative (any detectable estrogen and progesterone receptors do not express or express \<1%) and/or HER2 overexpression/amplified by FISH detection.
Not suitable for hormone receptor modulators (e.g. tamoxifen) and adjuvant endocrine other drug therapy.
